...
机译:切换到Doravirine / Lamivudine / Tenofovir Disoproxil富马酸盐(DOR / 3TC / TDF)通过48周维持HIV-1病毒学抑制:驱动转移试验的结果
Royal Free Hosp Dept HIV Med London England;
Medstar Georgetown Univ Hosp Div Infect Dis &
Travel Med Washington DC USA;
Univ Paris Diderot Hop St Louis Paris France;
ASST Fatebenefratelli Sacco Hosp Dept Infect Dis Milan Italy;
Fdn Huesped Buenos Aires DF Argentina;
Infektiologikum Ctr Infect Dis Frankfurt Germany;
Hosp Clin Barcelona HIV Unit Infect Dis Serv Barcelona Spain;
Merck &
Co Inc Kenilworth NJ USA;
Merck &
Co Inc Kenilworth NJ USA;
Merck &
Co Inc Kenilworth NJ USA;
Merck &
Co Inc Kenilworth NJ USA;
Merck &
Co Inc Kenilworth NJ USA;
Merck &
Co Inc Kenilworth NJ USA;
Merck &
Co Inc Kenilworth NJ USA;
doravirine; HIV-1; treatment-experienced; noninferiority;
机译:切换到Doravirine / Lamivudine / Tenofovir Disoproxil富马酸盐(DOR / 3TC / TDF)通过48周维持HIV-1病毒学抑制:驱动转移试验的结果
机译:Doravirine / Lamivudine / Tenofovir Disoproxil富马酸莫特是非低于Efavirenz / Emtrickabine / Tenofovir Disoproxil富马酸富马酸莫汀,治疗野生成年人具有人免疫缺陷病毒-1感染:周48结果的推动前试验结果
机译:从基于Efavirenz的方案转换为Doravirine-Lamivudine-Tenofovir Disoproxil富马酸核富马酸核
机译:LB2。切换至Doravirine /拉米夫定/替诺福韦富马酸二甲酚(DOR / 3TC / TDF)可以在48周内保持病毒学抑制:DRIVE-SHIFT试验的结果
机译:LB2。切换到Doravirine / Lamivudine / Tenofovir Disocroxil富马酸盐(DOR / 3TC / TDF)通过48周保持病毒学抑制:驱动转移试验的结果